Clinical trials: Refractory/Relapsed Chronic Lymphocytic Leukemia
- Condition Refractory/Relapsed Chronic Lymphocytic Leukemia
- Funder type Industry (pharma, biotech, devices)
Chronic Lymphocytic Leukemia
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
- Trial name
- NCT02157324
- Testing
- acalabrutinib, ACP-319
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Acerta Pharma BV
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb